<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diacetylmorphine (diamorphine) (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diacetylmorphine (diamorphine) (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diacetylmorphine (diamorphine) (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="137881" href="/d/html/137881.html" rel="external">see "Diacetylmorphine (diamorphine) (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F49104476"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Analgesic, Opioid</li></ul></div>
<div class="block doa drugH1Div" id="F49104497"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d55b3bb-0aaf-4b8c-bd73-27aac1fd99f2">Opioid use disorder, maintenance treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder, maintenance treatment: Note:</b> Individualize dosing regimen based on patient-specific factors (eg, comorbidities, severity of pain, concomitant medications, cachexia, general condition, degree of opioid experience/tolerance) and titrate to patient-specific treatment goals. Patients may receive supplemental oral opioid agonist therapy or transition to methadone to minimize withdrawal symptoms between doses. Patients may administer the injections, however, patients must be supervised by health care providers experienced in the treatment of severe opioid use disorder and trained in the administration of injectable opioid agonist therapy; patients must be monitored for 15 to 30 minutes after diamorphine administration for signs of withdrawal, overdose, respiratory depression, or sedation in health care settings where emergency naloxone and resuscitation equipment is available and cardiopulmonary resuscitation can be performed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, IV:</b> Initiate therapy over several days and titrate to response (see "Example Initiation Regimens" below).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Example initiation regimens:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Initiation:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">
<b>Two Doses per Day (CRISM 2019)</b></span></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 1:</b></p>
<p style="text-indent:-2em;margin-left:10em;">Dose 1: <b>IM, IV:</b> 30 mg, then observe for 15 minutes; if no intoxication symptoms, administer 60 mg based on clinical judgement and discussion with patient; observe for 15 minutes. Administer next dose in 3 to 12 hours. Total possible dose = 90 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Dose 2: <b>IM, IV:</b> If dose 1 is well tolerated, administer 90 mg and observe for 15 minutes; if no intoxication symptoms, administer 60 mg based on clinical judgement and discussion with patient; observe for 15 minutes. Administer next dose the following day. Total possible dose = 150 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 2: </b></p>
<p style="text-indent:-2em;margin-left:10em;">Dose 1: <b>IM, IV:</b> Administer 100 mg and observe for 15 minutes; if no intoxication symptoms, administer 60 mg based on clinical judgement and discussion with patient; observe for 15 minutes. Administer next dose in 3 to 12 hours. Total possible dose = 160 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Dose 2: <b>IM, IV:</b> Administer 160 mg and observe for 15 minutes; if no intoxication symptoms, administer 40 mg based on clinical judgement and discussion with patient; observe for 15 minutes. Administer next dose the following day. Total possible dose = 200 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 3:</b> Administer maximum tolerated single dose given during day 2 every 12 hours; observe for 15 minutes following every dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<span style="text-decoration: underline">
<b>Three Doses per Day (Oviedo-Joekes 2016</b>
<b>; Palis 2018; CRISM 2019</b>
<b>)</b></span></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 1: </b></p>
<p style="text-indent:-2em;margin-left:10em;">Dose 1: <b>IM, IV:</b> 15 mg, then observe for 15 minutes; if no intoxication symptoms, administer 30 mg based on clinical judgement and discussion with patient; observe for 15 to 30 minutes. Administer next dose in 3 to 8 hours. Total possible dose = 45 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Dose 2: <b>IM, IV:</b> If dose 1 is well tolerated, administer 45 mg and observe for 15 to 30 minutes; if no intoxication symptoms, administer 30 mg based on clinical judgement and discussion with patient; observe for 15 to 30 minutes. Administer next dose in 3 to 8 hours. Total possible dose = 75 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Dose 3: <b>IM, IV:</b> If previous doses are well-tolerated, administer 75 mg and observe for 15 to 30 minutes; if no intoxication symptoms, administer 30 mg based on clinical judgement and discussion with patient; observe for 15 to 30 minutes. Administer next dose the following day. Total possible dose = 105 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 2: </b></p>
<p style="text-indent:-2em;margin-left:10em;">Dose 1: <b>IM, IV:</b> Administer 40% of total daily dose at day 1 (up to a total of 90 mg if all doses on day 1 were tolerated) and observe for 15 to 30 minutes; if no intoxication symptoms, administer 30 mg based on clinical judgement and discussion with patient; observe for 15 to 30 minutes. Administer next dose in 3 to 8 hours. Total possible dose = 120 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Dose 2: <b>IM, IV:</b> Administer maximum tolerated amount of dose 1 (up to 120 mg) and observe for 15 to 30 minutes; if no intoxication symptoms, administer 30 mg based on clinical judgement and discussion with patient; observe for 15 to 30 minutes. Administer next dose in 3 to 8 hours. Total possible dose = 150 mg.</p>
<p style="text-indent:-2em;margin-left:10em;">Dose 3: <b>IM, IV:</b> Administer maximum tolerated amount of dose 2 (up to 150 mg) and observe for 15 to 30 minutes; if no intoxication symptoms, administer 30 mg based on clinical judgement and discussion with patient; observe for 15 to 30 minutes. Administer next dose the following day. Total possible dose = 180 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Day 3:</b> Administer maximum tolerated single dose given during day 2 every 8 hours; observe for 15 to 30 minutes following every dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Maintenance:</b>
<b>IM, IV: </b>Adjust dosage once a week based on response and tolerability. Maximum single dose: 400 mg; maximum daily dose: 1 <b>g</b>/day.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Missed dose:</b> If treatment is interrupted, re-initiation of dose titration may be needed, starting at a decreased dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Conversion to oral methadone: </b>During transition to or from diamorphine, ensure dose of methadone is properly calculated so patient receives the same degree of saturation of opioid receptors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Discontinuation of therapy: </b>When indicated, gradually taper under medical supervision.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992439"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 20 to 50 mL/minute: Administer 75% of usual initial dose; titrate cautiously to response.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 10 to 20 mL/minute: Administer 50% of usual initial dose; titrate cautiously to response.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;10 mL/minute or hemodialysis: Use not recommended.</p></div>
<div class="block doha drugH1Div" id="F50989687"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Initiate treatment at the lowest possible dose and titrate slowly with extended dosing intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F49104499"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Minimize opioid use in older adults unless for the management of severe acute pain. Opioids are associated with an increased risk of falls and inducing or worsening delirium in older adults (Beers Criteria [AGS 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">Initiate at a lower dose and slowly titrate to effect.</p></div>
<div class="block adr drugH1Div" id="F243056"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults and may include concomitant methadone.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (4% to 43%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site pruritus (30%), injection-site reaction (43%; including injection-site pruritus and urticaria at injection site)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Nervous system: Drowsiness (9%), seizure (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Circulatory depression, shock</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, decreased gastrointestinal motility, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, local hypersensitivity reaction, and severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drug abuse, opioid dependence</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema, presyncope, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Altered hormone level (decreased luteinizing hormone and follicle stimulating hormone), amenorrhea, increased serum glucose, increased serum prolactin, loss of libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Biliary colic, decreased appetite, delayed gastric emptying, paralytic ileus</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary hesitancy, urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, anxiety, asthenia, chills, confusion, disorientation, dysphoria, emotional lability, euphoria, fatigue, feeling abnormal, hallucination, increased intracranial pressure, lethargy, malaise, myoclonus, neonatal withdrawal, nervousness, nightmares, paresthesia, serotonin syndrome, tremor, withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia, laryngospasm</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, diplopia, miosis, nystagmus disorder, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, dyspnea, respiratory depression</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug tolerance</p></div>
<div class="block coi drugH1Div" id="F243064"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to diamorphine, other opioid agonists, or any component of the formulation; patients without opioid use disorder and who are not currently taking high doses or high concentrations of opioids; known or suspected mechanical GI obstruction (eg, bowel obstruction, strictures); diseases/conditions that affect bowel transit (eg, ileus of any type); acute or severe bronchial asthma; chronic obstructive airway; status asthmaticus; acute respiratory depression; elevated carbon dioxide levels; cor pulmonale; acute alcohol use disorder; delirium tremens; seizures; severe CNS depression; increased cerebrospinal fluid; increased intracranial pressure; head injury; concomitant use with monoamine oxidase inhibitors or within 2 weeks of their discontinuation; patients with signs of intoxication, including due to centrally acting sedatives, stimulants, or other acute condition that would increase the risk of adverse effects; bipolar disorder, schizophrenia, or other psychiatric disorders with active psychotic symptoms refractory to medical management.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F243054"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Generalized and localized hypersensitivity reactions may occur at the injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute myocardial infarction), circulatory shock, or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Avoid use in patients with circulatory shock. Avoid rapid IV injection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: <b>[Canadian Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. </b>Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. Patients and caregivers should be educated on how to recognize respiratory depression and the importance of getting emergency assistance immediately (eg, calling 911) in the event of known or suspected overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: May occur with concomitant use of serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants [TCAs]), lithium, St John's wort, agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors), or agents that impair metabolism of tramadol (eg, CYP2D6 and 3A4 inhibitors). Symptoms may include mental status changes (eg, agitation, hallucinations, coma); autonomic instability (eg, tachycardia, labile BP, hyperthermia); neuromuscular changes (eg, hyperreflexia, incoordination); and/or GI symptoms (eg, nausea, vomiting, diarrhea).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">• Biliary tract impairment: Use with caution in patients with biliary tract dysfunction or acute pancreatitis; opioids may cause constriction of sphincter of Oddi.</p>
<p style="text-indent:-2em;margin-left:4em;">• Coagulation disorders: Use with caution in patients with coagulation disorders.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Use with caution in patients with injection-related infections (eg, sepsis, endocarditis, pneumonia, infective osteomyelitis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to potential increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with decreased respiratory reserve, hypoxia, hypercarbia, or preexisting respiratory depression, particularly when initiating therapy and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: <b>[Canadian Boxed Warning]: Use with caution in patients with seizure disorders or at risk for seizures (eg, head trauma, metabolic disorders, alcohol and drug withdrawal, CNS infections, concurrent use with other medications that reduce seizure threshold).</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related disorders: Use with caution in patients with sleep-related disorders, including sleep apnea, due to increased risk for respiratory and central nervous system depression. Monitor carefully and titrate dosage cautiously in patients with mild sleep-disordered breathing. Avoid opioids in patients with moderate to severe sleep-disordered breathing (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concurrent drug therapy issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzodiazepines or other CNS depressants: <b>[Canadian Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, somnolence, respiratory depression, coma, and death. Antidepressants (eg, TCAs) may increase risk of arrhythmias, seizures, and affect thyroid levels. Reserve concomitant prescribing of morphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b> Consider prescribing naloxone for emergency treatment of opioid overdose in patients taking benzodiazepines or other CNS depressants concomitantly with opioids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ethanol use: Patients should not consume alcoholic beverages or medication containing ethanol while taking diamorphine; ethanol may increase plasma levels, resulting in a potentially fatal overdose.</p>
<p style="text-indent:0em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Neonatal withdrawal syndrome: <b>[Canadian Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn, which may be life-threatening.</b> Signs and symptoms include irritability, hyperactivity, abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older patients: Use opioids with caution in older adults; may be more sensitive to adverse effects. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increased adverse effects. Monitor closely for adverse effects associated with opioid therapy (eg, respiratory and central nervous system depression, falls, cognitive impairment, constipation) (CDC [Dowell 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt discontinuation/withdrawal: Abrupt discontinuation or missed doses in patients who are physically dependent on opioids has been associated with serious withdrawal symptoms, uncontrolled pain, attempts to find other opioids (including illicit), and suicide. Use a collaborative, patient-specific taper schedule that minimizes the risk of withdrawal, considering factors such as current opioid dose, duration of use, type of pain, and physical and psychological factors. Diacetylmorphine interruption may require starting at a decreased dose for patient safety as rapid loss in tolerance may result in increased risk of overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: <b>[Canadian Boxed Warning]:</b>
<b>Diamorphine exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient's risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b>
<b>Store securely to avoid theft and diversion.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental exposure: <b>[Canadian Boxed Warning]: Use care to reduce risk of accidental exposure during reconstitution; ensure all syringes are properly and securely stored.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b>[Canadian Boxed Warning]:</b>
<b>For use only in opioid-tolerant patients requiring high concentrations of opioid agonists under a health care provider trained in the treatment of opioid use disorder and the provision of opioid agonist therapy. Initiate treatment slowly. Assess patient to determine readiness to leave the health care setting and ensure safe transportation is available. Do not inject into the jugular or femoral vein; </b>jugular vein thrombosis, deep neck infections, pneumothorax, endocarditis, and sepsis may occur.<b> Should only be administered in facilities equipped and staffed to immediately recognize severe adverse reactions (eg, respiratory depression, seizures); </b>
<b>resuscitative equipment, oxygen, naloxone, and other resuscitative drugs should be available for immediate use. </b>Use with caution in patients who cannot safely self-inject medication (eg, poor venous access, poor injection technique).</p>
<p style="text-indent:-2em;margin-left:4em;">• Naloxone access: Discuss the availability of naloxone with all patients who are prescribed opioid analgesics, as well as their caregivers, and consider prescribing it to patients who are at increased risk of opioid overdose. These include patients who are also taking benzodiazepines or other CNS depressants, have an opioid use disorder (OUD) (current or history of), or have experienced opioid-induced respiratory depression/opioid overdose. Additionally, health care providers should consider prescribing naloxone to patients prescribed medications to treat OUD; patients at risk of opioid overdose, even if they are not taking an opioid analgesic or medication to treat OUD; and patients taking opioids, including methadone or buprenorphine for OUD, if they have household members, including children, or other close contacts at risk for accidental ingestion or opioid overdose. Inform patients and caregivers on options for obtaining naloxone (eg, by prescription, directly from a pharmacist, a community-based program) as permitted by state dispensing and prescribing guidelines. Educate patients and caregivers on how to recognize respiratory depression, proper administration of naloxone, and getting emergency help.</p></div>
<div class="block prod-avail drugH1Div" id="F49104512"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F57571244"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F57571246"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (1 ea); 5000 mg (1 ea)</p></div>
<div class="block csi drugH1Div" id="F56839710"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-I</p></div>
<div class="block accres drugH1Div" id="F56839709"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;">Only available through controlled distribution.</p></div>
<div class="block adm drugH1Div" id="F49104504"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IM, IV:</b> May administer by supervised self-injection IM or IV; do not inject into the jugular or femoral vein. Use proper injection techniques to minimize risk of infection.</p></div>
<div class="block use drugH1Div" id="F243061"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Opioid use disorder, maintenance treatment:</b> Maintenance treatment of opioid use disorder in adult patients who use injectable opioids and have failed previous attempts at opioid agonist therapy (including methadone); in conjunction with an individualized, comprehensive, opioid dependence treatment program (eg, medical, psychological, social support).</p></div>
<div class="block mst drugH1Div" id="F49104473"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diamorphine may be confused with morphine or hydromorphone.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diamorphine may be confused with Diamox brand name for acetazolamide (various countries), Dimorf brand name for morphine (Brazil), and Duramorph brand name for morphine (United States).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute of Safe Medication Practices (ISMP) includes among its list of drug classes that have heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See "Warnings/Precautions" section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between dosing diamorphine and morphine or diamorphine oral and IV dosing. Use caution when converting from one drug to the other or from one route of administration to another.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F49322567"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F243057"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of Diamorphine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alvimopan: Opioid Agonists may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the analgesic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Diamorphine may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Diamorphine may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the CNS depressant effect of Opioid Agonists. Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Opioid Agonists may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diuretics: Opioid Agonists may enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Opioid Agonists may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Opioid Agonists may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Diamorphine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: Opioid Agonists may enhance the adverse/toxic effect of Nalfurafine. Opioid Agonists may diminish the therapeutic effect of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalmefene: May diminish the therapeutic effect of Opioid Agonists. Management: Avoid the concomitant use of oral nalmefene and opioid agonists. Discontinue oral nalmefene 1 week prior to any anticipated use of opioid agonists. If combined, larger doses of opioid agonists will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naltrexone: May diminish the therapeutic effect of Opioid Agonists. Management: Seek therapeutic alternatives to opioids. See full drug interaction monograph for detailed recommendations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Diamorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Agonists. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Diamorphine may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: Opioid Agonists may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May increase serum concentrations of the active metabolite(s) of Diamorphine. Management: Use caution and reduce the diamorphine dose during coadministration with quinidine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Opioid Agonists may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease serum concentrations of the active metabolite(s) of Diamorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Diamorphine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: May diminish the therapeutic effect of Opioid Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk): Opioid Agonists may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Somatostatin Analogs: Opioid Agonists may diminish the analgesic effect of Somatostatin Analogs. Opioid Agonists may enhance the analgesic effect of Somatostatin Analogs. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: May enhance the bradycardic effect of Opioid Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tryptophan: Diamorphine may enhance the serotonergic effect of Tryptophan. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56839755"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients who could become pregnant should be offered pregnancy screening prior to injectable opioid agonist treatment (iOAT) (CRISM 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Amenorrhea has been reported following diamorphine use. Chronic opioid use may cause hypogonadism and hyperprolactinemia, which may decrease fertility in patients of reproductive potential. Menstrual cycle disorders (including amenorrhea), erectile dysfunction, and impotence have been reported. The incidence of hypogonadism may be increased with the use of opioids in high doses or long-acting opioid formulations. It is not known if the effects on fertility are reversible. Monitor patients on long-term therapy (de Vries 2020; Gadelha 2022).</p>
<p style="text-indent:0em;margin-top:2em;">Contraception should be discussed with patients undergoing iOAT (CRISM 2019).</p></div>
<div class="block pri drugH1Div" id="F243066"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Opioids cross the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of opioids may be associated with poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Neonatal abstinence syndrome (NAS)/neonatal opioid withdrawal syndrome (NOWS) may occur following prolonged in utero exposure to opioids (CDC [Dowell 2022]). NAS/NOWS may be life-threatening if not recognized and treated and requires management according to protocols developed by neonatology experts. Presentation of symptoms varies by opioid characteristics (eg, immediate release, sustained release), time of last dose prior to delivery, drug metabolism (maternal, placental, and infant), net placental transfer, as well as other factors (AAP [Hudak 2012]; AAP [Patrick 2020]). Clinical signs characteristic of withdrawal following in utero opioid exposure include excessive crying or easily irritable, fragmented sleep (&lt;2 to 3 hours after feeding), tremors, increased muscle tone, or GI dysfunction (hyperphagia, poor feeding, feeding intolerance, watery or loose stools) (Jilani 2022). NAS/NOWS occurs following chronic opioid exposure and would not be expected following the use of opioids at delivery (AAP [Patrick 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Opioid agonist pharmacotherapy is recommended for pregnant patients with an opioid use disorder (CRISM 2018; SOGC [Ordean 2017]). However, data related to injectable opioid agonist treatment (iOAT) during pregnancy are limited and oral treatment should be considered prior to initiating or continuing iOAT in pregnant patients (CRISM 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Monitor neonates for symptoms of withdrawal (SOGC [Ordean 2017]).</p></div>
<div class="block brc drugH1Div" id="F49104477"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Opioids are present in breast milk; the amount of diamorphine in breast milk is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">Infants exposed to diamorphine via breast milk are at risk for life-threatening respiratory depression. Consider the potential benefit to the mother and the potential risk to the breastfed infant prior to use in breastfeeding patients.</p></div>
<div class="block mop drugH1Div" id="F49104511"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for signs of withdrawal, overdose, respiratory depression, and sedation during administration and for 30 minutes following administration; signs of intoxication, withdrawal, and to avoid diversion prior to initiation, during, and after injection; signs of injection-related infections; symptoms of hypotension following initiation or dose titration; signs of serotonin syndrome; signs of misuse, abuse, and substance use disorder.</p></div>
<div class="block pha drugH1Div" id="F243053"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A potent morphine opiate derivative with CNS depressant effects, increases smooth muscle tone, and causes the release of histamine and catecholamines.</p></div>
<div class="block phk drugH1Div" id="F243063"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: IV: 0.3 minutes; IM: 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IV: 1 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: 5 minutes diacetylmorphine, metabolite 6-monoacetylmorophine peaks within 6 minutes, and morphine within 17 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: IV: 37 ± 16 L; active metabolite: 60 to 100 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 20% to 40% to albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly hydrolyzed to active metabolites 6-monoacetylmorphine (further metabolized to morphine) by serum and liver esterases; some morphine-glucuronides are excreted in the bile and are hydrolyzed into morphine in the colon resulting in enterohepatic recirculation and additional contribution to total bioavailability of morphine.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: IM: 380% ± 157%; ≥3 to 4 times greater than IV administration; metabolite 6-monoacetylmorophine mean 120% ± 30% and morphine 134% ± 54% compared to IV administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Active metabolites: Terminal: 2 to 6.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: IM: 5 minutes; active metabolites: 6 to 17 minutes; IV: 0.7 to 5.1 hours; active metabolite: 0.3 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (70%; 55% as conjugated morphine).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49056142"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Diaphin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Diagesil | Diamorphine | Diamorphine aurum | Diamorphine chiron | Diamorphine napp | Diamorphine roche</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diamorphine hydrochloride wockhardt | Diaphin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23414717">
<a name="23414717"></a>Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi:10.1016/j.amjmed.2012.12.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/23414717/pubmed" id="23414717" target="_blank">23414717</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Canadian Research Initiative in Substance Misuse (CRISM). National injectable opioid agonist treatment for opioid use disorder clinical guideline. https://crism.ca/projects/ioat-guideline/. Published September 23, 2019. Accessed July 29, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CRISM.2017">
<a name="CRISM.2017"></a>Canadian Research Initiative in Substance Misuse (CRISM). National guideline for the clinical management of opioid use disorder. https://crism.ca/projects/opioid-guideline/. Published 2018. Accessed June 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31511863">
<a name="31511863"></a>de Vries F, Bruin M, Lobatto DJ, et al. Opioids and their endocrine effects: a systematic review and meta-analysis. <i>J Clin Endocrinol Metab</i>. 2020;105(3):1020-1029. doi:10.1210/clinem/dgz022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/31511863/pubmed" id="31511863" target="_blank">31511863</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Diacetylmorphine hydrochloride (diamorphine hydrochloride) [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36327391">
<a name="36327391"></a>Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain - United States, 2022. <i>MMWR Recomm Rep</i>. 2022;71(3):1-95. doi:10.15585/mmwr.rr7103a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/36327391/pubmed" id="36327391" target="_blank">36327391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35066756">
<a name="35066756"></a>Gadelha MR, Karavitaki N, Fudin J, Bettinger JJ, Raff H, Ben-Shlomo A. Opioids and pituitary function: expert opinion. <i>Pituitary.</i> 2022;25(1):52-63. doi:10.1007/s11102-021-01202-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/35066756/pubmed" id="35066756" target="_blank">35066756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22291123">
<a name="22291123"></a>Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn; American Academy of Pediatrics. Neonatal drug withdrawal. <i>Pediatrics</i>. 2012;129(2):e540-e560. doi:10.1542/peds.2011-3212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/22291123/pubmed" id="22291123" target="_blank">22291123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34942181">
<a name="34942181"></a>Jilani SM, Jones HE, Grossman M, et al. Standardizing the clinical definition of opioid withdrawal in the neonate. <i>J Pediatr.</i> 2022;243:33-39.e1. doi:10.1016/j.jpeds.2021.12.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/34942181/pubmed" id="34942181" target="_blank">34942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28935057">
<a name="28935057"></a>Ordean A, Wong S, Graves L. No. 349-substance use in pregnancy. <i>J Obstet Gynaecol Can.</i> 2017;39(10):922-937.e2. doi:10.1016/j.jogc.2017.04.028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/28935057/pubmed" id="28935057" target="_blank">28935057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25452049">
<a name="25452049"></a>Oviedo-Joekes E, Sordo L, Guh D, et al. Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence. <i>Addict Behav</i>. 2015;41:81-86. doi:10.1016/j.addbeh.2014.10.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/25452049/pubmed" id="25452049" target="_blank">25452049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29892701">
<a name="29892701"></a>Palis H, Marchand K, Karamouzian M, et al. The association between nicotine dependence and physical health among people receiving injectable diacetylmorphine or hydromorphone for the treatment of chronic opioid use disorder. <i>Addict Behav Rep</i>. 2018;7:82-89. doi:10.1016/j.abrep.2018.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/29892701/pubmed" id="29892701" target="_blank">29892701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33106341">
<a name="33106341"></a>Patrick SW, Barfield WD, Poindexter BB; Committee on Fetus and Newborn; Committee on Substance Use and Prevention. Neonatal opioid withdrawal syndrome. <i>Pediatrics.</i> 2020;146(5):e2020029074. doi:10.1542/peds.2020-029074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diacetylmorphine-diamorphine-united-states-not-available-drug-information/abstract-text/33106341/pubmed" id="33106341" target="_blank">33106341</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 139300 Version 31.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
